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Background: The effects of transforming growth factor-beta (TGFβ) are mediated by the transcription factors Smad2
and Smad3. During adult skeletal myogenesis, TGFβ signaling inhibits the differentiation of myoblasts, and this can be
reversed by treatment with retinoic acid (RA). In mesenchymal stem cells and preadipocytes, RA treatment can function
in a non-classical manner by stimulating the expression of Smad3. Smad3 can bind to and prevent the bzip transcription
factor CCAAT/enhancer-binding protein beta (C/EBPβ) from binding DNA response elements in target promoters, thereby
affecting cell differentiation. In skeletal muscle, C/EBPβ is highly expressed in satellite cells and myoblasts and is
downregulated during differentiation. Persistent expression of C/EBPβ in myoblasts inhibits their differentiation.
Methods: Using both C2C12 myoblasts and primary myoblasts, we examined the regulation of C/EBPβ expression and
activity following treatment with TGFβ and RA.
Results: We demonstrate that treatment with RA upregulates Smad3, but not Smad2 expression in myoblasts, and can
partially rescue the block of differentiation induced by TGFβ. RA treatment reduces C/EBPβ occupancy of the
Pax7 and Smad2 promoters and decreased their expression. RA also inhibits the TGFβ-mediated phosphorylation
of Smad2, which may also contribute to its pro-myogenic activities. TGFβ treatment of C2C12 myoblasts stimulates
C/EBPβ expression, which in turn can stimulate Pax7 and Smad2 expression, and inhibits myogenesis. Loss of C/EBPβ
expression in myoblasts partially restores differentiation in the presence of TGFβ.
Conclusions: TGFβ acts, at least in part, to inhibit myogenesis by upregulating the expression of C/EBPβ, as treatment
with RA or loss of C/EBPβ can partially rescue differentiation in TGFβ-treated cells. This work identifies a pro-myogenic
role for Smad3, through the inhibition of C/EBPβ’s actions in myoblasts, and reveals mechanisms of crosstalk between
RA and TGFβ signaling pathways.
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The canonical transforming growth factor-beta (TGFβ)
pathway involves the binding of dimerized TGFβ family
ligands to a constitutively active TGFβ type II cell sur-
face receptor [1]. Ligand binding by the type II receptor
promotes its association with the TGFβ type I receptor
that is both phosphorylated and activated by the type II
receptor [2]. The activated type I receptor then phos-
phorylates receptor Smad transcription factors (Smad2* Correspondence: Nadine.WiperBergeron@uottawa.ca
2Department of Cellular and Molecular Medicine, Faculty of Medicine,
University of Ottawa, Ottawa, Ontario, Canada
Full list of author information is available at the end of the article
© 2015 Lamarche et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and Smad3), which bind to Smad4 and translocate to the
nucleus to regulate gene transcription [3,4]. Activation and
consequent nuclear translocation of Smad2 and Smad3 by
the TGFβ type 1 receptor is achieved by phosphorylation
of distinct serine residues (Ser465/467 for Smad2 and
Ser423/425 for Smad3) in their respective C-terminal
tails [5-7].
While much is known about the activation of Smad3
activity, very little is known about the transcriptional path-
ways regulating Smad3 expression and the functional
consequences of this activation in different cell systems.
Smad3 expression is inhibited by isoprenoids in a Sp1/
Sp3-dependent fashion [8], and mitogen-activated proteinral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sion, by inhibiting Sp1 binding to a region between −849
and −408 of the Smad3 promoter [9]. Treatment with ret-
inoic acid (RA) has also been shown to upregulate Smad3
mRNA expression in T cells, mesenchymal stem cells, and
preadipocytes [10,11].
During myogenesis, treatment with TGFβ is known to
potently, yet reversibly, inhibit the differentiation process
[12-19]. TGFβ signaling can inhibit myogenesis through
activation of Smad3, which can interfere with the for-
mation of muscle regulatory factor-containing transcrip-
tional complexes [12,13]. The muscle phenotype has been
investigated in a Smad3 knockout model, in which a
premature stop was introduced in exon 7, producing a
truncated Smad3 lacking the C-terminal 89 amino acids
encoded by exon 8, which contains the serine residues
phosphorylated by the activated TGFβ type I receptor
[18,20,21]. Loss of the C-terminal domain crippled TGFβ-
mediated responses. Interestingly, Smad3 knockout mice
had fewer satellite cells, the muscle stem cell primarily
responsible for regeneration and repair; reduced myoblast
proliferation; and smaller fiber caliber [20]. Moreover,
muscle regeneration after acute injury was also reduced
in the Smad3 knockout mice [21]. These findings sug-
gested that Smad3 assumes a pro-myogenic role in muscle
precursors, in sharp contrast to the potently anti-myogenic
role of TGFβ signaling.
While both Smad2 and Smad3 bind the same DNA re-
sponse element in target promoters and are both activated
by the same receptor, there is growing evidence that
these factors are not redundant in function. In the kidney,
where TGFβ induces tubulo-interstitial fibrosis, Smad3
and Smad2 have been shown to regulate a different subset
of genes [22,23]. In pancreatic ductal adenocarcinoma,
Smad3 and Smad2 exert opposite effects on growth and
cellular migration, and in primed pluripotent cells, Smad3
was shown to be dispensable for the maintenance of the
undifferentiated state [24,25]. Indeed, TGFβ has even been
shown to inhibit the expression of Smad3 [26] further
suggesting that Smad3 can counteract Smad2 activities
in some systems.
In mesenchymal stem cells and preadipocytes, treatment
with RA has been shown to influence the differentiation
of adipocytes and osteoblasts at least in part by stimulat-
ing the expression of Smad3. In these systems, Smad3 acts
in a non-classical manner, in that it is not C-terminally
phosphorylated, but nonetheless affects the expression of
CCAAT/enhancer-binding protein alpha (C/EBPα) and
Runx2, the master regulators of adipogenesis and osteo-
blastogenesis, respectively [11,18,27-30]. Both C/EBPα
and Runx2 are transcriptional targets of C/EBPβ, a bzip
transcription factor involved in numerous cellular differ-
entiation processes. C/EBPβ interacts with the Smad3
MH1 domain, which blocks C/EBPβ’s ability to bind itsDNA response elements in target promoters. As such,
increased Smad3 levels can abrogate C/EBPβ-mediated
transcriptional responses [11]. During adipogenesis, RA
treatment and the consequent increase in Smad3 expres-
sion prevents interaction of C/EBPβ with the C/EBPα
promoter, decreasing expression of the master regulator
resulting in the inhibition of differentiation. In contrast,
RA can promote osteoblastogenesis by preventing C/EBPβ
from interacting with the Runx2 promoter, where it acts
as a negative regulator [27,29].
In muscles, C/EBPβ is expressed in satellite cells where
it acts to maintain the undifferentiated state. Induction
of satellite cells to differentiate is accompanied by a de-
crease in C/EBPβ expression; loss of satellite cell marker
Pax7 expression, a C/EBPβ target gene; and the induction
of myogenic regulatory factors such as myogenin [31].
Herein, we identify C/EBPβ as a novel TGFβ target gene
that mediates, at least in part, the anti-myogenic effects of
this signaling pathway. We demonstrate that C/EBPβ ex-
pression is upregulated by TGFβ treatment, and this leads
to an increase in C/EBPβ target gene expression. Further,
we identify Smad2 as a novel C/EBPβ target, creating an
anti-myogenic feed-forward control loop. Loss of C/EBPβ
expression, or interference with its ability to bind DNA




Protein extracts were harvested with protease and phos-
phatase inhibitors (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and were analyzed using the following anti-
bodies: C/EBPβ (C-19, Santa Cruz Biotechnology), Smad2/
3 (Cell Signaling Technology, Danvers, MA, USA), myo-
genin, Pax7, and myosin heavy chain (MF-20) primary
antibodies from DSHB (Iowa City, IA, USA); and
phospho Smad2/3 (Abcam, Cambridge, U.K.). β-Actin
(Sigma-Aldrich, St-Louis, MO, USA) was used as a
loading control. HRP-conjugated secondary antibodies
were from GE Healthcare (Buckinghamshire, U.K.).
Chemiluminescence images were captured using the
Luminescent Image Analyzer LAS-4000 (Fujifilm Life
Science, Tokyo, Japan), and quantifications were done
using ImageJ (U.S. National Institutes of Health, Bethesda,
MD, USA, http://imagej.nih.gov/ij/, 1997–2014).
Cell culture
C2C12 myoblasts (ATCC, Manassas, VA, USA) were cul-
tured and maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Wisent, Saint-Bruno, QC, Canada) con-
taining 4.5 g/L glucose, 110 mg/L sodium pyruvate, and
584 mg/L L-glutamine and supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad,
CA, USA). To stimulate skeletal muscle differentiation,
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containing 1% heat-inactivated horse serum (HS; Invitrogen)
for 4 days. 3T3L1 cells (ATCC) were maintained in DMEM
containing 4.5 g/L glucose, 110 mg/L sodium pyruvate,
and 584 mg/L L-glutamine and supplemented with 10%
heat-inactivated calf serum (HI-CS, Invitrogen). Primary
myoblasts were freshly isolated from wild-type and C/EBPβ
conditional knockout mice as previously described [31].
Briefly, a tamoxifen-sensitive CreER DNA recombinase
driven by the Pax7 locus was used to excise Cebpb from
homozygous mice bearing Loxp sites inserted on both ends
of the Cebpb coding sequence. Excision of Cebpb was
achieved with a 48 h treatment of isolated primary
myoblasts with 2 μM 4-OH tamoxifen (Sigma-Aldrich).
Isolated primary myoblasts were cultured in DMEM sup-
plemented with 1% penicillin and streptomycin (Wisent)
containing 20% FBS, 10% HS, 10 ng/ml FGF (Peprotech,
Rocky Hill, NJ, USA), and 2 ng/ml HGF (Peprotech).
Culture media and growth factors were replenished every
day. Upon reaching confluence, primary myoblasts were
switched to DMEM containing 2% FBS and 10% HS (low
serum conditions) for 2 days in the presence of TGFβ or
vehicle. Media and TGFβ were replenished every day.
Retroviral infection
Replication-incompetent pLXSN-based retroviruses
(Clontech, Palo Alto, CA, USA) were generated in
Phoenix Ampho packaging cells (ATCC) and have been
described previously [30]. Virus was harvested 48 h after
transfection. Following infection of C2C12 myoblasts, cells
were selected in growth medium supplemented with
400 ug/mL G418 for 7 days to generate pooled stable
cell lines.
Reagents
All-trans retinoic acid (Sigma-Aldrich) was used at a con-
centration of 1 nM. TGFβ1 (R&D Systems, Minneapolis,
MN, USA) was used at a concentration of 1 ng/ml for
C2C12 cells and 5 ng/ml for primary myoblasts and chan-
ged every 24 h for the duration of the treatment.
RT-qPCR
For quantitative reverse transcription polymerase chain
reaction (RT-qPCR), total RNA was extracted using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) and con-
taminating DNA was digested with DNase (Ambion, Life
Technologies, Austin, TX, USA). Subsequently, RNA
was reverse transcribed using the iScript kit (Bio-Rad,
Hercules, CA, USA) according to manufacturer’s in-
structions. Real-time PCR reactions were performed with
iTaq SYBR Green (Bio-Rad) on a Mx3005p thermocycler
(Stratagene, La Jolla, CA, USA). Relative fold induction
was determined using the ΔΔCt method [32] following
normalization with 18S rRNA.Differentiation and fusion indices
To assess differentiation of C2C12 cells and primary
myoblasts, immunohistochemistry was performed using
anti-myosin heavy chain antibody (MF-20) from DHSB,
which recognizes the fast and slow sarcomeric myosin
heavy chains. The antibody was incubated overnight,
followed by a Cy3-conjugated donkey anti-mouse IgG sec-
ondary antibody (Jackson ImmunoResearch, West Grove,
PA, USA) for 1 h. DAPI (0.5 μg/ml) counterstain was
used to label chromatin. Pictures were taken of a mini-
mum of six random field of view at × 10 magnification
per well. The differentiation index is defined as the
number of myosin heavy chain positive nuclei divided
by the total number of nuclei. The fusion index is de-
scribed as the number of myosin heavy chain positive
nuclei in myotubes divided by the total number of
myotubes.
Chromatin immunoprecipitation assay
C2C12 myoblasts were cultured in growth or differenti-
ation conditions and treated with RA or vehicle for
24 h as indicated. Chromatin immunoprecipitation (ChIP)
analysis was performed as described [30] using antibodies
for C/EBPβ (C-19; Santa Cruz Biotechnology), RAR
(M-454; Santa Cruz Biotechnology), or non-immunized
normal rabbit IgG (Invitrogen) as control, incubating at
4°C overnight. After sonication, DNA fragments were
purified using the QIAquick PCR Purification Kit (Qiagen)
and amplified by qPCR. Primer sequences for the Pax7
promoter were as follows: forward 5′-CCCGAACTGGC
CCCCTTTCC-3′ and reverse 5′-TCCCCCGGAGGACTG
GAACG-3′. Primer sequences for the intronic RARE
region of the Smad3 promoter were as follows: forward
5′-ATGACTTGTTCCTGTCCTTC-3′ and reverse 5′-
GCTAGGCAGAGTTCCCAGAA-3′. Primer sequences
for the Smad2 promoter were as follows: forward 5′-
AAGTCCCTGGAGGGAATGGA-3′ and reverse 5′-C
ACTGTAGGCAGAGCAGGTT-3′.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, La Jolla, CA, USA, www.
graphpad.com). The student’s t test was used when com-
paring a control and experimental condition in one group.
One-way ANOVA followed by Tukey’s post-hoc test was
used when comparing one factor in three or more groups.
Two-way ANOVA followed by Bonferroni’s post-hoc test
was used when comparing two factors in control and
experimental conditions. Post-hoc tests followed only
statistically significant ANOVA results (p < 0.05). Where
multiple comparisons are possible, means are marked
with a letter code. Means with different letters are sig-
nificantly different from one another, meeting a mini-
mum cutoff of P < 0.05. All experiments are representative
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cated. Data represents the mean; error bars represent
the SEM.Figure 1 Retinoic acid upregulates Smad3 expression in myoblasts.
(A) RT-qPCR analysis of Smad3 mRNA expression in C2C12 myoblasts
cultured in growth medium and treated with vehicle or RA for
48 h. Data is shown as fold expression over vehicle-treated condition.
Error bars are the SEM, *P < 0.05, n = 3. (B) RT-qPCR analysis of Smad3
mRNA expression in C2C12 myoblasts cultured in differentiation
medium and treated with vehicle or RA for 48 h. Data is shown as
fold expression over vehicle-treated condition. Error bars are the
SEM; *P < 0.05, n = 3. (C) Schematic representation of the mouse
Smad3 locus found on the minus strand of chromosome 9 using
the Mouse Dec. 2011 (GRCm38/mm10) Assembly. Location of the
transcript, including 5′ and 3′ UTRs, is indicated as well as the predicted
CpG island (%CG = 65.9%, length = 1,436 bp, ObsCpG/ExpCpG =0.80).
The position of a RARE identified by ChIP-seq analysis in ES cells
undergoing neurogenesis (GSM482750) between exon 3 and 4 of
the Smad3 gene is also indicated. (D) Analysis of retinoic acid receptor
(RAR) occupancy of the RARE in the intronic region of the mouse
Smad3 gene by chromatin immunoprecipitation and qPCR in C2C12
cells in growth medium. Data represents the mean; error bars are the
SEM; *P < 0.05, n = 3.Results
RA regulates Smad3 expression in myoblasts
Consistent with our observations in mesenchymal stem
cells and preadipocytes, both proliferating myoblasts cul-
tured in growth medium (GM) and myoblasts cultured in
low serum conditions to induce differentiation (differenti-
ation medium, DM) had increased Smad3 mRNA expres-
sion following treatment with 1 nM RA (Figure 1A,B)
[11,27]. Treatment with RA resulted in a significant 3-fold
increase in Smad3 mRNA expression in growth medium
as compared to vehicle-treated controls (Figure 1A). Simi-
larly, under differentiation conditions, a 2-fold increase in
Smad3 mRNA was observed as compared to vehicle-
treated controls (Figure 1B). It should be noted that 1 nM
RA did not adversely affect cell growth or differentiation,
while higher concentrations of RA were toxic to the cells
(Additional file 1: Figure S1).
In silico analysis of the mouse Smad3 gene and the
upstream 5-kb region of the predicted promoter re-
vealed no canonical retinoic acid response elements
(RARE) by which RA could induce transcription by
binding to the retinoic acid receptor: retinoid X recep-
tor (RAR:RXR) heterodimer. Indeed, the promoters driv-
ing expression of Smad3 in mouse, rat, and humans are
quite divergent, with the exception of large CpG islands
(Figure 1C). These CG-rich regions are prone to methyla-
tion, and it has previously been demonstrated that the
co-Smad Smad4 is silenced through this mechanism
[33]. Methylation of the Smad3 promoter has also been
demonstrated in humans [34]. Despite this, incorpor-
ation of 5-azacytidine (AZA), a methylation-resistant
cytosine analog, failed to induce Smad3 expression des-
pite significantly increasing Rarb expression, a RA tar-
get gene that is also regulated through a CpG island
[35]. A 24-h treatment with AZA, however, failed to in-
duce Smad3, suggesting that methylation of the CpG is-
land is not the primary mode of regulation for Smad3
expression (Additional file 2: Figure S2 A,B). Published
ChIP-seq data in which RAR occupancy of DNA elements
in embryonic stem cells were mapped [GSM482750]
confirmed that RARs do not occupy the promoter re-
gion of Smad3 in mice, but rather appear to occupy a
site in the intron between exons 3 and 4 of the gene
(Figure 1C). ChIP analysis of RAR occupancy of the pu-
tative intronic RARE revealed a significant 4-fold en-
richment when compared to IgG controls in C2C12
myoblasts (Figure 1D), suggesting that occupancy of this
site by RARs may play a role in the regulation of Smad3
expression by RA.Treatment with retinoic acid rescues TGFβ-induced
inhibition of myogenesis
TGFβ is a well-known reversible inhibitor of myogenesis
[12-16,19]. In our experiments, when C2C12 myoblasts
were treated with 1 ng/ml TGFβ, cell differentiation in
low serum conditions was inhibited, with only a few small
myosin heavy chain-expressing cells observed (Figure 2A).
The differentiation index (#myonuclei/#total nuclei) of
Figure 2 Retinoic acid partially rescues the inhibition of myogenesis induced by TGFβ. (A) Representative images of C2C12 myoblasts
differentiated in low serum conditions in the continual presence of RA or TGFβ as indicated or with vehicle (Veh) for 96 h and immunostained
for myosin heavy chain (MyHC) expression. DAPI is used to reveal nuclei (blue). (B) Differentiation index (#myonuclei/#total nuclei) of C2C12
cells cultured and treated as in (A). Means indicated with the same letter are not statistically different from one another. Means with different
letters are significantly different from one another with a P < 0.05, n = 3. (C) Fusion index (#myonuclei/#myotubes) of C2C12 cells cultured and
treated as in (A). Calculations include mononucleated myosin heavy chain positive cells. Means with different letters are significantly different
from one another with a P < 0.05, n = 3. (D) RT-qPCR analysis of Smad3, Smad2, Pax7, and myogenic marker expression in C2C12 myoblasts
treated and differentiated as in (A). Means with different letters are significantly different from one another with a P < 0.05, n = 3. (E) Western
analysis of phosphorylated Smad2/3 (pSmad2/3) expression in C2C12 cells in growth conditions. Quantification by densitometry is represented
as pSmad2 or pSmad3 relative to actin, respectively, n = 3, **P < 0.01, NS = not significant. Protein levels for Smad2 and Smad3 are shown.
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index (#myonuclei/#myotubes) was reduced 63%, as com-
pared to vehicle-treated cells (Figure 2B,C). In contrast,
treatment with RA alone resulted in a modest but signifi-
cant increase in differentiation, as compared to vehicle-
treated cells (Figure 2A,B) [36-39]. Fusion was
unaffected by treatment with RA (Figure 2C). When
C2C12 myoblasts were treated with both RA and TGFβ,
the differentiation index was partially restored to 55%
of vehicle-treated cells (Figure 2A,B), while the fusion
index was restored to vehicle-treated levels (Figure 2C).
To better understand the blockade of differentiation in
TGFβ-treated cells, RT-qPCR analysis of mRNA expres-
sion in C2C12 myoblasts after 96 h in DM was performed
(Figure 2D). RA treatment resulted in a significant in-
crease in Smad3 and Myog expression, but did not affect
the expression of Smad2, Pax7, Myf5, or Myod1 as com-
pared to vehicle-treated controls (Figure 2D). By contrast,
treatment with TGFβ significantly increased Pax7 and
Myf5 expression, while decreasing Myod1 and Myog ex-
pression (Figure 2D), suggesting a blockade in differenti-
ation in these cells. Smad3 and Smad2 mRNA expressions
were not affected by TGFβ treatment at this time point
(Figure 2D). Co-treatment with both TGFβ and RA sig-
nificantly reduced Pax7 expression as compared to TGFβ
treatment alone and restored Myog expression to the level
of vehicle-treated controls, without affecting Myf5 or
Myod1 levels (Figure 2D). Taken together, this data sug-
gests that RA treatment can partially reverse the inhibitory
effects of TGFβ on myoblasts.
Since the inhibition of C/EBPβ activities by Smad3 in
preadipocytes and osteoblasts was mediated by Smad3
that was not phosphorylated on its C-terminal tail, as
occurs with TGFβ treatment, we examined the classical
Smad2/3 C-terminal serine phosphorylation sites in C2C12
myoblasts following a 24-h treatment with TGFβ and RA
(Figure 2E). Western analysis to detect phospho-Smad2/3
revealed that while treatment with RA did not induce
C-terminal phosphorylation of either Smad, treatment
with TGFβ in the presence or absence of RA resulted in
robust phosphorylation of the Smad3 S423 and S425
residues (Figure 2E). These results suggest that the ef-
fects of RA on TGFβ-mediated signaling are not due to
changes in Smad3 phosphorylation status. However, in
cells treated with both TGFβ and RA, we did detect a
significant decrease in Smad2 phosphorylation of the
equivalent residues without changes in Smad2 levels
(Figure 2E), suggesting that RA may interfere with the
actions of TGFβ by reducing Smad2 activation by
phosphorylation.
TGFβ treatment of myoblasts stimulates C/EBPβ expression
Given that TGFβ treatment could enhance Pax7 expres-
sion in myoblasts and that Pax7 is a C/EBPβ target genein myoblasts [31], we examined C/EBPβ expression levels
in TGFβ and RA-treated cells. A 96-h TGFβ treatment of
differentiating C2C12 myoblasts resulted in robust 8-fold
increase in C/EBPβ expression (Figure 3A,B). TGFβ treat-
ment also resulted in a 6-fold increase in Pax7 expression
(Figure 3A,C). We next evaluated the effect of RA on C/
EBPβ expression. While RA treatment did not change C/
EBPβ expression, co-treatment with both TGFβ and RA
under these conditions trended towards decreased C/
EBPβ expression, but this failed to meet statistical signifi-
cance when compared to TGFβ-treated cells (Figure 3D,
E). RT-qPCR analysis revealed that while RA had no effect
on Cebpb mRNA under differentiation conditions, TGFβ
could upregulate Cebpb mRNA expression by approxi-
mately 2-fold under differentiation conditions, as com-
pared to vehicle treatment, and this was prevented with
TGFβ and RA co-treatment (Figure 3F). Taken together,
these results suggest that C/EBPβ expression is regulated
by TGFβ signaling and its expression can be inhibited by
co-treatment with RA.
RA interferes with C/EBPβ occupancy of target genes
One of the consequences of enhanced Smad3 nuclear ex-
pression in the absence of robust C-terminal phosphoryl-
ation in preadipocytes and mesenchymal stem cells is
interference with the transcriptional activities of C/EBPβ
[31]. We therefore predicted that RA treatment would de-
crease C/EBPβ occupancy of key target genes during myo-
genesis. We have previously demonstrated that Pax7 is a
target gene of C/EBPβ in myoblasts and that C/EBPβ
binds to a DNA response element in the Pax7 promoter
[31]. To determine if RA promotes myogenesis by inter-
fering with the activity of C/EBPβ, we performed a chro-
matin immunoprecipitation (ChIP) assay to evaluate C/
EBPβ occupancy of the Pax7 promoter in C2C12 myo-
blasts. Since induction to differentiate rapidly reduces
Pax7 expression, we treated C2C12 myoblasts for 24 h
with RA in growth medium and analyzed C/EBPβ occu-
pancy (Figure 4A). C/EBPβ was readily detected at the
Pax7 promoter in vehicle-treated cells, and RA treatment
significantly reduced the occupancy of C/EBPβ at its re-
sponse element (Figure 4A). We repeated the ChIP in
C2C12 myoblasts induced to differentiate for 24 h in the
presence or absence of RA and found that RA treatment
also decreased C/EBPβ occupancy of the Pax7 promoter
as compared to vehicle-treated cells (Figure 4B).
To correlate changes in occupancy with changes in
gene expression, the expression of Pax7 was evaluated
following a 24-h RA treatment under growth conditions
(Figure 4C). Pax7 expression was unaffected by RA
treatment in GM, a condition where C/EBPβ promoter
occupancy was reduced. However, under differentiation
conditions, RA treatment significantly reduced the expres-
sion of Pax7 (Figure 4D), suggesting that the regulation of
Figure 3 TGFβ treatment stimulates C/EBPβ expression in myoblasts. (A)Western analysis of C/EBPβ and Pax7 expression in C2C12 myoblasts
cultured in differentiation medium in the presence or absence of TGFβ for 96 h. Actin is used as a loading control. (B) Quantification of C/EBPβ expression
from western blots in panel (A) relative to vehicle-treated controls. Error bars are the SEM, n= 3, *P< 0.05. (C) Quantification of Pax7 expression from
western blots from (A) relative to vehicle-treated controls. Error bars are the SEM, n= 3, **P< 0.01. (D) C/EBPβ protein expression after 96 h in differentiation
medium (DM) in the continual presence of TGFβ and/or RA, as indicated. Actin is used as a loading control. (E) Quantification of western blots from (D)
relative to the vehicle-treated controls. Error bars represent the SEM. Means marked with different letters are statistically different, meeting a minimum
cutoff of P< 0.05, n= 4. (F) Cebpb mRNA expression in C2C12 myoblasts induced to differentiate in the presence or absence of TGFβ and RA for 96 h. Data
is shown relative to vehicle-treated controls, and error bars are the SEM, n= 3. Means marked by different letters are statistically different from one another,
meeting the minimum cutoff of P< 0.05.
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the actions of C/EBPβ as compared to DM conditions.
Since TGFβ treatment increased C/EBPβ expression
(Figure 3A), and persistent expression of C/EBPβ inhibits
myogenic differentiation [31], we next examined the regu-
lation of Smad2 and Smad3 in cells overexpressing C/
EBPβ. We created pooled stable cell lines by retroviral
transduction of C2C12 myoblasts to express C/EBPβ or
empty virus control (pLXSN) and then treated the cells
with RA for 48 h in growth medium (Figure 4E,F). RA
treatment stimulated Smad3 expression in empty virus
control cells and C/EBPβ-overexpressing cells (Figure 4E,
F). Overexpression of C/EBPβ resulted in a stimulation of
Smad2 expression that was reduced when cells weretreated with RA (Figure 4E,F), suggesting that RA can
interfere with Smad2 expression increased by C/EBPβ.
Indeed, in primary myocytes isolated from a conditional
null model in which C/EBPβ is excised in Pax7+ cells
(Figure 4G), the mRNA expression of Smad2 was re-
duced by approximately 60% (Figure 4H). ChIP analysis
revealed that C/EBPβ could occupy the Smad2 promoter
in growth conditions (Figure 4I), and this occupancy was
reduced to control IP levels by RA treatment, suggesting
that RA treatment can also prevent C/EBPβ occupancy of
the Smad2 promoter. The reduction in occupancy was ac-
companied by a significant decrease in Smad2 mRNA ex-
pression in RA-treated cells in both growth medium and
under differentiation conditions (Figure 4J,K), indicating
Figure 4 RA interferes with C/EBPβ occupancy of target genes. (A) C/EBPβ occupancy of the Pax7 promoter in C2C12 myoblasts in GM after
24-h +/- RA. n = 3. (B) C/EBPβ occupancy of the Pax7 promoter in C2C12 myoblasts after 24-h in DM, +/-RA. n = 3. (C) Pax7 expression in C2C12
myoblasts after 24 h +/- RA in GM. n = 3. (D) Pax7 expression in C2C12 myoblasts after 24 h +/-RA in DM. n = 3. (E) Smad2/3 and C/EBPβ expression in
C2C12 myoblasts retrovirally transduced to express C/EBPβ or with empty virus (pLXSN) +/- RA for 48 h in GM. Actin is the loading control.
(F) Quantification of blots from (E); *P< 0.05, compared to vehicle-treated empty virus controls; **P< 0.01, compared to C/EBPβ-overexpressing vehicle-
treated cells, n≥ 3. (G) C/EBPβ expression in primary myoblasts from C/EBPβ conditional null (cKO) or control (WT) muscle in GM.. Quantification of three
trials is indicated, with control set to 100, P < 0.05. (H) Smad2 expression in control (WT) and cKO myoblasts in GM. n = 3. (I) ChIP analysis of
C/EBPβ occupancy of the Smad2 promoter in C2C12 myoblasts after 24-h +/- RA in GM. n = 3. (J) Smad2 expression in C2C12 myoblasts treated for
24 h +/-RA in GM. n = 3. (K) Smad2 expression in C2C12 myoblasts treated for 24 h +/-RA in DM. n = 3. (L) Cebpb expression in cells cultured as in (J).
(M) Cebpb expression in cells cultured as in (K). n = 3. For all graphs, data is the mean +/- SEM. Means marked with different letters are statistically
different from one another, meeting a minimum cutoff of P < 0.05. *P < 0.05, **P < 0.01. NS = non significant.
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raising the possibility that RA-upregulated Smad3
could prevent Smad2 upregulation and thereby pro-
mote myogenesis.
C/EBPβ can also autoregulate its expression [40-42].
Following a 24-h RA treatment under growth conditions,
Cebpb expression was reduced, though not significantly
(p < 0.06) (Figure 4L). However, under differentiation con-
ditions, RA treatment significantly reduced the expression
of Cebpb (Figure 4M), suggesting that RA treatment can
decrease the expression of genes that inhibit myogenesis.
Inhibition of myogenesis by TGFβ is partially rescued by
loss of C/EBPβ in myoblasts
Given that C/EBPβ expression is enhanced by TGFβ
treatment, we hypothesized that TGFβ inhibits myogenic
differentiation at least in part through the induction of C/
EBPβ expression. We isolated primary myoblasts from a
conditional knockout model (cKO; Cebpbfl/fl/Pax7CreER/+)
and from control mice (WT; Cebpbfl/fl/Pax7+/+) and in-
duced excision of Cebpb in cells expressing CreER with
4-OH tamoxifen. Primary myoblasts differentiate more
rapidly than C2C12 myoblasts when exposed to low
serum conditions, requiring a shorter time point for
evaluation of differentiation. Myogenic differentiation was
quantified using immunocytochemistry directed at myosin
heavy chain in both WT and cKO cultures (Figure 5A).
Vehicle-treated cKO myoblasts differentiated and fused
similarly to WT controls (Figure 5A–C). The low dose of
TGFβ used (5 ng/ml), however, decreased the number of
myosin heavy chain positive cells in WT primary cells, de-
creasing the differentiation index by 67% as compared to
vehicle-treated controls (Figure 5B). Of the TGFβ-treated
WT cells that did differentiate, their fusion was severely
compromised, with a fusion index (excluding mono-
nuclear cells) reduced by 45% as compared to vehicle-
treated controls (Figure 5C). The cKO primary myoblasts
were less sensitive to the effects of TGFβ, with a differenti-
ation index significantly higher than WT TGFβ-treated
cells, but still distinct from controls (37% decrease
as compared to vehicle-treated WT cells) (Figure 5B).
The fusion of cKO cells treated with TGFβ, while
trending towards restoration, was not statistically dif-
ferent from TGFβ-treated WT cells or vehicle-treated
controls (Figure 5C), indicating a partial restoration of
myogenesis with loss of C/EBPβ. Indeed, we have ob-
served previously that the conditional loss of C/EBPβ
can enhance myoblast fusion [31].
RT-qPCR analysis of myogenic gene expression was
performed 48 h after induction to differentiate in the
presence or absence of TGFβ in both WT and cKO cells
(Figure 5D). TGFβ treatment decreased Smad3 expres-
sion, and this was not dependent on Cebpb expression.
Smad2 expression was decreased with loss of C/EBPβbut was not affected by TGFβ treatment. Pax7 expres-
sion was increased by TGFβ treatment in WT cells, but
was unaffected by loss of Cebpb expression. Both Myf5
and Myod1 were decreased by TGFβ treatment of WT
cells, and this was not rescued by concomitant loss of
Cebpb. Surprisingly, despite a partial rescue of the differ-
entiation index, Myog expression was unchanged by TGFβ
treatment and was unchanged in the cKO cells. Further,
MyHC expression was, however, decreased by TGFβ treat-
ment in cells of both genotypes. However, western analysis
revealed that while the trends we observe at the mRNA
level are preserved in protein expression for C/EBPβ and
Smad3, myogenin protein expression is restored to con-
trol levels in TGFβ-treated cKO cells following differen-
tiation, consistent with our differentiation assay results
(Figure 5E,F). Further, myosin heavy chain expression was
also increased in the TGFβ-treated cKOs as compared to
the WTs though not restored to vehicle-treated levels,
suggesting only a partial rescue of differentiation, which
can be accounted for by the incomplete knockdown of C/
EBPβ in the cKO cells. Smad2 protein levels were also not
significantly affected by TGFβ treatment or loss of C/
EBPβ expression at this time point, in contrast to changes
in mRNA expression.
Taken together, these results suggest that TGFβ acts in
part to inhibit myogenic differentiation through the ac-
tions of C/EBPβ, either through stimulation of its expres-
sion as observed in C2C12 myoblasts or by decreasing
Smad3 expression, which is known to interact with and
inhibit the DNA occupancy of C/EBPβ.
Discussion
Our results place the bzip transcription factor C/EBPβ
as a mediator of TGFβ signaling in myoblasts (Figure 6).
TGFβ treatment of C2C12 myoblasts stimulates C/EBPβ
expression which in turn stimulates the expression of
Pax7 and Smad2 as well as autoregulating itself in both
growth and differentiation conditions. Indeed, C/EBPβ is
known to regulate its own expression through binding
to C/EBP elements in its promoter [40-42]. TGFβ treat-
ment also decreased Smad3 expression, as was observed
in human osteoarthritic chondrocytes, but this was not
dependent on C/EBPβ [26]. Treatment with RA in-
creased Smad3 levels in both growth and differentiation
conditions, and decreased C/EBPβ occupancy of its tar-
get genes Pax7 and Smad2, resulting in a decrease in
the expression of these factors and the stimulation of
myogenesis. RA treatment also reduced the phosphoryl-
ation of Smad2 in TGFβ-treated cells without affecting
Smad3 phosphorylation suggesting a second possible
mechanism by which RA can promote myogenesis.
Despite robust upregulation of C/EBPβ expression in
TGFβ-treated C2C12 myoblasts, and a role for C/EBPβ
in the maintenance of Smad2 mRNA expression under
Figure 5 (See legend on next page.)
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Figure 5 Inhibition of myogenesis by TGFβ is partially rescued by loss of C/EBPβ expression. (A) Representative images of myosin heavy
chain expression by immunocytochemistry in primary myoblasts isolated from cKO or control (WT) mouse hindlimb and induced to differentiate
in low serum for 48 h in the absence (veh) or presence of TGFβ treatment. (B) Differentiation indices (#myonuclei/#total nuclei) of cells cultured
and treated as in (A). Means marked by different letters are statistically different from one another, with a minimum of P < 0.05, n = 3. Error bars
represent the SEM (C) Fusion indices (#myonuclei/#myotubes) of cells cultured and treated as in (A). Counts exclude mononucleated myosin
heavy chain positive cells. Error bars represent the SEM; means marked by different letters are statistically different from one another, meeting a
minimum cutoff of P < 0.05, n = 3. (D) RT-qPCR analysis of Smad2, Smad3, Cebpb, Pax7, and myogenic marker expression in primary myoblasts
differentiated as in (A). Means with different letters are significantly different from one another with a P < 0.05, n ≥ 3. (E) Representative western
blots of C/EBPβ, Smad2, Smad3, myogenin, and myosin heavy chain in primary myoblasts differentiated as in (A). Means with different letters are
significantly different from one another with a P < 0.05, n = 5. (F) Quantification of C/EBPβ, Smad2, Smad3, myogenin, and myosin heavy chain protein
expression from (E) relative to vehicle-treated WT control cells. Error bars are the SEM. Means marked with different letters are statistically different from
one another, meeting a minimum cutoff of P < 0.05, n ≥ 3.
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serve a consistent upregulation of Smad2 or Cebpb ex-
pression by TGFβ in the primary myoblasts, while Pax7
was upregulated. Despite this, in primary myoblasts in
which C/EBPβ expression was knocked down, differenti-
ation was partially restored, suggesting that C/EBPβ is
an important mediator of the anti-myogenic effects of
TGFβ. In the absence of TGFβ treatment and in primary
myoblasts, Smad2 expression is readily detectable andFigure 6 Proposed pro-myogenic role for retinoic acid and
Smad3. The bzip transcription factor C/EBPβ is a potent inhibitor of
myogenesis. It can stimulate the expression of Pax7 and Smad2 and
can autoregulate its own expression. Regulation of Pax7 expression
suppresses the myogenic differentiation of myoblasts, while the
contribution of Smad2 remains unknown. TGFβ treatment can
stimulate C/EBPβ expression during myogenic differentiation, and
this contributes in part to the anti-myogenic effects of TGFβ treatment
as loss of C/EBPβ partially restores differentiation in the presence
of TGFβ. TGFβ can also, upon binding its receptor, stimulate the
phosphorylation of both Smad2 and Smad3, and it is known that
Smad3 can form inhibitory complexes with myogenic regulatory
factors and inhibit myogenesis. Treatment with retinoic acid (RA)
can antagonize the effects of TGFβ during myogenesis. In particular,
RA can stimulate the expression of Smad3 which in turn associates
with C/EBPβ and reduces its occupancy of target gene promoters,
resulting in a reduction of their expression and the restoration
of differentiation. RA treatment can also prevent the normal
phosphorylation of Smad2 by the TGFβ receptor, without affecting
Smad3 phosphorylation.could transmit the effects of this signaling pathway inde-
pendent of C/EBPβ. Indeed, the stimulation of C/EBPβ
expression by TGFβ may serve to amplify the response
to TGFβ, rather than to mediate it entirely. However,
the partial rescue of differentiation suggests that TGFβ
also exerts anti-myogenic effects via other mechanisms.
While RA treatment restored fusion to control levels,
loss of C/EBPβ alone was unable to do so, despite only
partial restoration of differentiation in both models.
These results suggest that TGFβ can act independently
of C/EBPβ to inhibit myoblast fusion. Interestingly, of
the proteins known to be implicated in the fusion of
myoblasts, specifically ICAM-1, myomaker, Cdk16, and
IL-4, none have promoter regions bound by C/EBPβ
[43-47]. Further, the expression of myomaker and Cdk16,
based on Chip-seq data, appears to be targets of MyoD
and myogenin, and MyoD is known to be inhibited by ac-
tivated Smad3, providing a non-C/EBPβ-dependent mech-
anism for the inhibition of fusion by TGFβ [12,13,48].
The formation of Smad3-containing inhibitory complexes
with MEF2 and MyoD requires C-terminal phosphorylation
of serines 423/425 of Smad3 by the liganded TGFβ receptor
[12,13]. In RA-treated myoblasts, where Smad3 levels are
increased but Smad3 remains dephosphorylated, myogen-
esis is potentiated and can antagonize the actions of TGFβ.
As such, the phosphorylation of Smad3 by the TGFβ
receptor may act as a switch trigger, toggling between
the pro-myogenic actions of Smad3 in the absence of
serine 423/425 phosphorylation and the anti-myogenic
state when C-terminally phosphorylated. Indeed, RA
treatment had no impact on Smad3 serine 423/425 phos-
phorylation in our experiments (Figure 2E). This model is
consistent with the observation that loss of Smad3 in mice
produced smaller muscle fiber diameter, impaired muscle
regeneration following acute injury, and reduced satellite
cell activation [20,21]. Further, ChIP-seq studies in embry-
onic stem cells and myoblasts have shown that upon
TGFβ treatment, Smad3 co-occupies cell-specific DNA
sites with master transcription factors Oct4 and MyoD,
Lamarche et al. Skeletal Muscle  (2015) 5:8 Page 12 of 14respectively, an activity that, in myoblasts, stands paradox-
ically in opposition to the biological impact of TGFβ in
these cells [49]. However, if Smad3 has a pro-myogenic
role, it could help prime cells for efficient differentiation
by placing MyoD on target promoters. Further, a pro-
myogenic role for Smad3 is consistent with our own studies
which place RA-induced Smad3 as an important inhibitor
of C/EBPβ transcriptional activities in both preadipocytes
and mesenchymal stem cells, and an inhibitor of MyoD ex-
pression and activity in myoblasts [11,27,29,31].
Despite the absence of serine 423/425 phosphorylation
in RA-treated myoblasts, it is possible that Smad3, in
these cells, is alternatively phosphorylated or otherwise
post-translationally modified following RA treatment.
Indeed, numerous phosphorylation sites have been iden-
tified in the Smad3 linker region which can have an im-
pact on Smad3 nuclear-cytoplasmic localization, stability
and activity [50-54].
Therefore, it remains possible that in unspecified stem
cells and in early myogenesis, when C/EBPβ levels are
high and consequently MyoD levels are low, Smad3 ex-
pression can act to promote myogenesis at least in part
through the inhibition of C/EBPβ activity (Figure 6).
However, once C/EBPβ levels are downregulated, as they
are in C2C12 myoblasts, and MyoD expression increases,
Smad3 could become available to interfere with MyoD
and MEF2-containing transcriptional complexes and exert
an anti-myogenic role. As such, the inhibition of myogen-
esis by TGFβ may occur through at least two distinct
pathways, one mediated by C/EBPβ and a second occur-
ring downstream of myogenic regulatory factor activation.
Conclusions
We provide evidence that C/EBPβ is a non-canonical
regulator of TGFβ signaling. TGFβ signaling stimulates
C/EBPβ expression, which in turn increases Smad2 ex-
pression and Pax7 expression in myoblasts, inhibiting
differentiation. Loss of C/EBPβ expression, or interfer-
ence with C/EBPβ activity via RA treatment in myo-
blasts, resulted in a partial rescue of differentiation in
the presence of TGFβ, suggesting that TGFβ works at
least in part through C/EBPβ to inhibit myogenesis.
Additional files
Additional file 1: Figure S1. High doses of retinoic acid reduces C2C12
cell number. (A) C2C12 myoblasts were induced to differentiate in low serum
conditions for 96 h in the absence or presence of all-trans retinoic acid (RA)
at indicated doses. Cells were then fixed and subjected to immunostaining
for myosin heavy chain expression and counterstained with DAPI to reveal
nuclei. Representative images are shown. (B) DAPI cell counts per field of
view at increasing doses of RA in C2C12 cells differentiated as in (A) for 96 h.
Error bars are the SEM, *P< 0.05, NS = not significant, n= 5. (C) Crystal violet
assay measuring C2C12 cell number after 1, 2, or 3 days in growth medium
in the presence or absence of 1 nM RA, n= 3; error bars are the SEM.
Differences are not statistically significant.Additional file 2: Figure S2. Induction of Smad3 expression by RA is
direct. (A) Quantitative PCR analysis of Smad3 mRNA expression following
treatment of 3T3-L1 cells with RA or vehicle for 8 h and azacytidine (AZA) or
vehicle for 24 h. 5-Azacytadine (Sigma-Aldrich) was used at a concentration
of 3 μM. Data is represented as fold expression over vehicle-treated. Error
bars are the SEM. Means marked with different letters are statistically
different with a minimum threshold of P < 0.05, n = 3. (B) Quantitative PCR
analysis of Rarb2 mRNA following treatment of 3T3-L1 cells with RA or
vehicle for 8 h and azacytidine or vehicle for 24 h. Data is represented
as fold expression over vehicle-treated. Error bars are the SEM. Means
marked with different letters are statistically different with a minimum
cutoff of P < 0.05, n = 3.
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